BRPI1010666A2 - peptídeos de cdc45l e vacinas incluindo dos mesmos - Google Patents

peptídeos de cdc45l e vacinas incluindo dos mesmos

Info

Publication number: BRPI1010666A2
Authority: BR; Brazil
Prior art keywords: same; vaccines including; cdc45l peptides; cdc45l; peptides
Prior art date: 2009-05-26

Application number

BRPI1010666A

Other languages

English (en)

Inventor

Tsunoda Takuya

Nishimura Yasuharu

Nakamura Yusuke

Tomita Yusuke

Original Assignee

Oncotherapy Science Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-26

Filing date

2010-05-25

Publication date

2017-09-12

2010-05-25 Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc

2017-09-12 Publication of BRPI1010666A2 publication Critical patent/BRPI1010666A2/pt

2021-11-23 Publication of BRPI1010666B1 publication Critical patent/BRPI1010666B1/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/414—Nervous system antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/55—Lung

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Toxicology (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

BRPI1010666-9A 2009-05-26 2010-05-25 Composição farmacêutica, métodos para indução de célula apresentadora de antígeno com indutibilidade de linfócito t citotóxico e para indução de linfócito t citotóxico, bem como usos de peptídeos BRPI1010666B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US21713309P	2009-05-26	2009-05-26
US61/217,133		2009-05-26
PCT/JP2010/003488 WO2010137295A1 (en)	2009-05-26	2010-05-25	Cdc45l peptides and vaccines including the same

Publications (2)

Publication Number	Publication Date
BRPI1010666A2 true BRPI1010666A2 (pt)	2017-09-12
BRPI1010666B1 BRPI1010666B1 (pt)	2021-11-23

Family

ID=43222423

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1010666-9A BRPI1010666B1 (pt)	2009-05-26	2010-05-25	Composição farmacêutica, métodos para indução de célula apresentadora de antígeno com indutibilidade de linfócito t citotóxico e para indução de linfócito t citotóxico, bem como usos de peptídeos

Country Status (16)

Country	Link
US (1)	US8586547B2 (pt)
EP (4)	EP3556857B1 (pt)
JP (1)	JP5903697B2 (pt)
KR (1)	KR101765452B1 (pt)
CN (3)	CN102459589B (pt)
AU (1)	AU2010253356B2 (pt)
BR (1)	BRPI1010666B1 (pt)
CA (3)	CA3011607C (pt)
DK (3)	DK3208334T3 (pt)
ES (3)	ES2631952T3 (pt)
IL (1)	IL216211A (pt)
MX (1)	MX2011012619A (pt)
RU (1)	RU2562160C2 (pt)
SG (1)	SG176058A1 (pt)
TW (1)	TWI507204B (pt)
WO (1)	WO2010137295A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104066746B (zh) *	2011-10-28	2017-12-05	肿瘤疗法科学股份有限公司	Topk肽及包含它们的疫苗
EP3202783A1 (en) *	2016-02-02	2017-08-09	Ecole Polytechnique Fédérale de Lausanne (EPFL)	Engineered antigen presenting cells and uses thereof
PL4029494T3 (pl)	2017-01-25	2026-03-23	Ose Immunotherapeutics	Sposób wytwarzania stabilnej emulsji do dostarczania peptydów
SG11202002520UA (en)	2017-09-19	2020-04-29	Univ British Columbia	Anti-hla-a2 antibodies and methods of using the same
EP3684822A4 (en)	2017-09-20	2021-06-16	The University of British Columbia	NEW ANTI-HLA-A2 ANTIBODIES AND USES THEREOF

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4722848A (en)	1982-12-08	1988-02-02	Health Research, Incorporated	Method for immunizing animals with synthetically modified vaccinia virus
EP0239102A3 (en)	1986-03-28	1989-07-12	Tsuji, Kimiyoshi	Process for the formation of human-human hybridoma
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5108921A (en)	1989-04-03	1992-04-28	Purdue Research Foundation	Method for enhanced transmembrane transport of exogenous molecules
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5679647A (en)	1993-08-26	1997-10-21	The Regents Of The University Of California	Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en)	1993-08-26	1998-09-08	The Regents Of The University Of California	Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en)	1994-04-01	1998-04-14	Apollon, Inc.	Compositions and methods for delivery of genetic material
US5736524A (en)	1994-11-14	1998-04-07	Merck & Co.,. Inc.	Polynucleotide tuberculosis vaccine
US5922687A (en)	1995-05-04	1999-07-13	Board Of Trustees Of The Leland Stanford Junior University	Intracellular delivery of nucleic acids using pressure
WO1997005900A1 (en)	1995-08-03	1997-02-20	Rijksuniversiteit Te Leiden	Cell derived antigen presenting vesicles
US5853719A (en)	1996-04-30	1998-12-29	Duke University	Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja)	1996-07-26	2000-12-05	スローン―ケッタリングインスティチュートフォーキャンサーリサーチ	遺伝子的免疫化のための方法と試薬
US20030068623A1 (en) *	1997-06-16	2003-04-10	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
FR2766205B1 (fr)	1997-07-16	2002-08-30	Inst Nat Sante Rech Med	Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
JP4413429B2 (ja)	1998-06-25	2010-02-10	株式会社グリーンペプタイド	サイクロフィリンｂ由来の腫瘍抗原ペプチド
DK2336167T3 (da)	2001-03-14	2019-09-02	Dako Denmark As	MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi
CA2399569A1 (en)	2001-09-25	2003-03-25	Yusuke Nakamura	Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en)	2002-08-21	2005-02-16	Proimmune Ltd	Chimeric MHC protein and oligomer thereof
DE60327786D1 (de) *	2002-09-12	2009-07-09	Oncotherapy Science Inc	Kdr-peptide und diese enthaltende impfstoffe
WO2006031221A1 (en)	2004-09-13	2006-03-23	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Compositions comprising t cell receptors and methods of use thereof
JP4370409B2 (ja)	2005-06-22	2009-11-25	国立大学法人東北大学	がんの予後予測方法
EP2295570A1 (en)	2005-07-27	2011-03-16	Oncotherapy Science, Inc.	Method of diagnosing small cell lung cancer
EP2311985A1 (en) *	2005-07-27	2011-04-20	Oncotherapy Science, Inc.	Sirna for treating esophageal cancer
JP5276846B2 (ja)	2005-09-13	2013-08-28	国立大学法人三重大学	Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
AU2007259667B2 (en) *	2006-06-16	2012-06-14	Oncotherapy Science, Inc.	SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same
US8470534B2 (en)	2006-12-01	2013-06-25	Erik S. Knudsen	Methods of predicting resistance or sensitivity to therapies for cancer
TWI441648B (zh) *	2007-01-03	2014-06-21	Oncotherapy Science Inc	Ｆｏｘｐ３胜肽疫苗

2010
- 2010-05-21 TW TW099116260A patent/TWI507204B/zh not_active IP Right Cessation
- 2010-05-25 CN CN201080033325XA patent/CN102459589B/zh not_active Expired - Fee Related
- 2010-05-25 SG SG2011083813A patent/SG176058A1/en unknown
- 2010-05-25 EP EP19175920.8A patent/EP3556857B1/en active Active
- 2010-05-25 ES ES10780256.3T patent/ES2631952T3/es active Active
- 2010-05-25 DK DK17163532.9T patent/DK3208334T3/da active
- 2010-05-25 WO PCT/JP2010/003488 patent/WO2010137295A1/en not_active Ceased
- 2010-05-25 DK DK10780256.3T patent/DK2435567T3/en active
- 2010-05-25 EP EP10780256.3A patent/EP2435567B1/en not_active Not-in-force
- 2010-05-25 CA CA3011607A patent/CA3011607C/en active Active
- 2010-05-25 ES ES17163532T patent/ES2746334T3/es active Active
- 2010-05-25 BR BRPI1010666-9A patent/BRPI1010666B1/pt not_active IP Right Cessation
- 2010-05-25 AU AU2010253356A patent/AU2010253356B2/en not_active Ceased
- 2010-05-25 RU RU2011152975/10A patent/RU2562160C2/ru active
- 2010-05-25 EP EP21160385.7A patent/EP3868778A3/en not_active Withdrawn
- 2010-05-25 KR KR1020117030872A patent/KR101765452B1/ko not_active Expired - Fee Related
- 2010-05-25 CN CN201310610796.8A patent/CN103694315B/zh not_active Expired - Fee Related
- 2010-05-25 US US13/321,812 patent/US8586547B2/en not_active Expired - Fee Related
- 2010-05-25 DK DK19175920.8T patent/DK3556857T3/da active
- 2010-05-25 ES ES19175920T patent/ES2875950T3/es active Active
- 2010-05-25 CN CN201510386650.9A patent/CN105153279B/zh not_active Expired - Fee Related
- 2010-05-25 CA CA3167451A patent/CA3167451A1/en active Pending
- 2010-05-25 CA CA2762934A patent/CA2762934C/en active Active
- 2010-05-25 EP EP17163532.9A patent/EP3208334B1/en active Active
- 2010-05-25 MX MX2011012619A patent/MX2011012619A/es active IP Right Grant
- 2010-05-25 JP JP2011550339A patent/JP5903697B2/ja active Active
2011
- 2011-11-08 IL IL216211A patent/IL216211A/en active IP Right Grant

Also Published As

Publication number	Publication date
CN105153279B (zh)	2018-09-11
JP2012527867A (ja)	2012-11-12
CA2762934C (en)	2018-09-04
EP3868778A2 (en)	2021-08-25
ES2631952T3 (es)	2017-09-06
CA3011607C (en)	2022-09-13
IL216211A (en)	2016-06-30
KR101765452B1 (ko)	2017-08-07
CA2762934A1 (en)	2010-12-02
EP3868778A3 (en)	2021-11-03
RU2011152975A (ru)	2013-07-10
CA3011607A1 (en)	2010-12-02
EP3208334B1 (en)	2019-07-03
DK3208334T3 (da)	2019-09-30
CA3167451A1 (en)	2010-12-02
MX2011012619A (es)	2012-01-30
US8586547B2 (en)	2013-11-19
CN102459589B (zh)	2013-12-25
TW201106962A (en)	2011-03-01
ES2875950T3 (es)	2021-11-11
EP3556857A3 (en)	2019-12-04
BRPI1010666B1 (pt)	2021-11-23
ES2746334T3 (es)	2020-03-05
EP3208334A3 (en)	2017-10-18
CN103694315B (zh)	2015-07-29
EP3208334A2 (en)	2017-08-23
EP3556857A2 (en)	2019-10-23
EP2435567B1 (en)	2017-05-03
CN103694315A (zh)	2014-04-02
US20120164163A1 (en)	2012-06-28
IL216211A0 (en)	2012-01-31
JP5903697B2 (ja)	2016-04-20
EP3556857B1 (en)	2021-05-05
DK2435567T3 (en)	2017-07-24
AU2010253356B2 (en)	2015-09-24
EP2435567A4 (en)	2013-03-13
KR20120018203A (ko)	2012-02-29
TWI507204B (zh)	2015-11-11
DK3556857T3 (da)	2021-07-12
CN105153279A (zh)	2015-12-16
SG176058A1 (en)	2011-12-29
EP2435567A1 (en)	2012-04-04
RU2562160C2 (ru)	2015-09-10
CN102459589A (zh)	2012-05-16
AU2010253356A1 (en)	2011-12-01
WO2010137295A1 (en)	2010-12-02

Legal Events

Date	Code	Title	Description
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-10	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-12-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-06-16	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-05-18	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-08-17	B350	Update of information on the portal [chapter 15.35 patent gazette]
2021-09-14	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-11-23	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/05/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.
2024-03-19	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 14A ANUIDADE.
2024-07-09	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2776 DE 19-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BR112012004731A2 (pt)	2016-11-29	peptídeos derivados de wnt10 e uso dos mesmos
BRPI1009455A2 (pt)	2016-03-01	anticorpos anti-c40 e usos dos mesmos
PT2531206T (pt)	2017-09-05	Polipéptidos clorotoxina e conjugados e usos dos mesmos
PT2424896E (pt)	2015-11-30	Anticorpos anti-ceacam1 e métodos de utilização dos mesmos
BR112012006501A2 (pt)	2016-08-16	polipeptídios e usos dos mesmos
PT2427212T (pt)	2017-11-20	Anticorpos anti-cd100 e métodos para utilização dos mesmos
DK2552434T3 (da)	2019-06-11	Peptider og anvendelse deraf
PT3443970T (pt)	2020-10-09	Fagos antibacterianos, péptidos fágicos e métodos de utilização dos mesmos
PL2465864T3 (pl)	2015-03-31	Szczepionki z peptydem pochodzącym z Eph4
BRPI0912198A2 (pt)	2019-09-24	anticorpos anti-fn14 e usos dos mesmos
BR112013004175A2 (pt)	2016-05-10	aparelho e conjunto atuado piezoelétrico
BR112012001260A2 (pt)	2016-02-10	conjugados de epsilon-polilisina e o emprego dos mesmos
PT2580240T (pt)	2019-03-29	Anticorpos as100a4 e utilizações terapêuticas dos mesmos
BRPI1008887A2 (pt)	2016-03-01	peptídeos de foxm1 e vacinas contendo os mesmo
BRPI0914782A2 (pt)	2016-07-26	peptídeos de epítopos de cdca1 e vacinas contendo os mesmos
BR112012003844A2 (pt)	2016-11-16	vacinas de pttv e diagnóstico
IL229926A (en)	2016-11-30	Neil3 peptides and vaccines including the same
BRPI1011314A2 (pt)	2016-03-15	conjugados de albumina-peptídeo amilóide e usos dos mesmos
BRPI1010666A2 (pt)	2017-09-12	peptídeos de cdc45l e vacinas incluindo dos mesmos
BRPI1012312A2 (pt)	2017-03-21	peptídeos vangl1 e vacinas incluindo os mesmos
BRPI0923938A2 (pt)	2018-10-30	novos peptideos e uso dos mesmo
BRPI1013938A2 (pt)	2019-09-24	"peptídeos ttk e vacinas incluindo os mesmos"
BR112013013158A2 (pt)	2017-08-01	peptídeos de tomm34 e vacinas incluindo os mesmos
BRPI0919766A2 (pt)	2017-03-21	peptídeo de epítopo de rab6kifl/kif20a e vacinas contendo o mesmo
BRPI0923402A2 (pt)	2015-08-04	Peptídeos c10rf59 e vacinas incluindo os mesmos.